BidaskClub upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a strong sell rating to a sell rating in a research note released on Saturday.
NEOS has been the topic of several other reports. Zacks Investment Research downgraded shares of Neos Therapeutics from a hold rating to a sell rating in a research report on Thursday, January 25th. BMO Capital Markets downgraded shares of Neos Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, January 31st. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Neos Therapeutics and gave the stock a buy rating in a research report on Monday, January 8th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Neos Therapeutics presently has an average rating of Hold and a consensus target price of $14.00.
Neos Therapeutics (NASDAQ:NEOS) opened at $8.80 on Friday. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 4.01. The firm has a market cap of $256.60 and a price-to-earnings ratio of -2.57. Neos Therapeutics has a one year low of $6.30 and a one year high of $13.15.
TRADEMARK VIOLATION NOTICE: “Neos Therapeutics (NEOS) Lifted to Sell at BidaskClub” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3260513/neos-therapeutics-neos-lifted-to-sell-at-bidaskclub.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.